• Ancrod (current brand name: Viprinex) is a defibrinogenating agent derived from the venom of the Malayan pit viper. (wikipedia.org)
  • Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. (drugbank.com)
  • Matched Description: … Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom . (drugbank.com)
  • Thrombocytopenia as side effect has never been noticed with ancrod in contrast to heparin. (wikipedia.org)
  • In clinical trials for ischemic stroke, ancrod increased the risk of intracerebral hemorrhage. (wikipedia.org)
  • Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. (drugbank.com)
  • One of the cleavage fibrinogen products, termed 'desAA-Fibrin', acts as cofactor for the tPA-induced plasminogen activation and an increased fibrinolysis results in return (profibrinolytic activity of ancrod). (wikipedia.org)
  • The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ancrod. (drugbank.com)
  • Ancrod (current brand name: Viprinex) is a defibrinogenating agent derived from the venom of the Malayan pit viper. (wikipedia.org)
  • Scientists have developed an investigational agent, called ancrod (Viprinex), derived from the venom of the Malayan pit viper that offers the potential to extend the window of treatment opportunity. (20m.com)
  • In clinical trials for ischemic stroke, ancrod increased the risk of intracerebral hemorrhage. (wikipedia.org)
  • Ancrod in Acute Ischemic Stroke. (medscape.com)
  • Since we reviewed ancrod (Arvin - Berk) 5 years ago 1 it has been marketed and the reported indications for its use have widened. (bmj.com)
  • In medicine , ancrod is "an enzyme fraction from the venom of the Malayan pit viper, Agkistrodon rhodostoma . (citizendium.org)
  • Ancrod is the partly purified fraction of the venom of the Malayan pit viper (Agkistrodon rhodostoma). (bmj.com)
  • The blood viscosity in patients receiving ancrod is progressively reduced by 30 to 40% of the pretreatment levels. (wikipedia.org)
  • I.M.-Injection : Ancrod should not be injected i.m., because of rapid induction of neutralizing antibodies and thus drug resistance. (wikipedia.org)
  • appearance of neutralizing antibodies to ancrod with partial or total loss of ancrod activity (drug resistance). (wikipedia.org)
  • The half-life of ancrod is 3 to 5 hours and the drug is cleared from blood plasma, mainly renally. (wikipedia.org)
  • Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program. (medscape.com)